Letocha 2005.

Methods	Single centre, non blinded, RCT. No placebo control. Parallel trial.
Participants	18 children were randomised. Age range: 4 ‐ 13 years. OI type III and IV included.
Interventions	IV pamidronate versus control. Dosage: 10 mg/m2/day for 3 days every 3 months. Trial period: 12 months initially, then 7 participants in the treatment group were given an additional 6 ‐ 21 months of IV pamidronate. Note: 4 children in each group were receiving recombinant growth hormone (rGH) (0.06 mg/kg/day for 6 days/week). All participants were seen quarterly at the National Institutes of Health Clinical Center. Serum markers of bone formation and growth parameters were measured at each visit. Antero‐posterior (AP) and lateral radiographs of the spine and lower extremity long bones and DXA at vertebrae L1–L4 were obtained at baseline and every 6 months. QCT scans of the spine were performed at the National Institutes of Health Clinical Center at 0 and 12 months.
Outcomes	L1 ‐ L4 DXA, spine QCT, spine radiographs, musculoskeletal and functional testing.
Notes	Allocation of intervention ‐ adequate. "Randomly‐generated numbers".
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly‐generated numbers.
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Trial was stated as non‐blind but during measurements, the investigator was blinded to participant identifiers, the order of the films, and whether they came from the treatment or control groups.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	A per protocol and repeated‐measures model was used. It is not clear if all randomised participants completed the trial.
Selective reporting (reporting bias)	High risk	Reported no significant change in biochemical markers of bone and mineral metabolism.
Other bias	Low risk	None.